Vera Therapeutics (VERA) announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy in adults. Participants treated with atacicept achieved a 46% reduction from baseline in proteinuria, with a statistically significant and clinically meaningful 42% reduction in urine protein-to-creatinine ratio compared to placebo at week 36. Vera plans to share the results with the FDA in the coming weeks.
ORIGIN 3 is an ongoing global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial of 431 adults with IgA nephropathy. The trial continues in a placebo-controlled blinded manner to evaluate the change in kidney function over two years and is expected to complete in 2027.
Shares of Vera Therapeutics are up 71% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.